Tag: anti-SARS-CoV-2 plasma product
CSL Behring Australia Commences Development of Treatment for Serious Cases of COVID-19
Media Release
CSL Behring Australia, a subsidiary of CSL Limited, today announced that it will begin immediate onshore development of an anti-SARS-CoV-2 plasma product with...
Featured Article
Reducing downtime through real-time shop floor insights with Minitab’s Prolink
Unplanned downtime remains one of the most costly – and often misunderstood – challenges on the manufacturing floor.
